CASE REPORT
Biphenotypic sinonasal sarcoma with PAX3/FOXO1 fusion
1
Department of Pathology, University of Health Sciences, Umraniye Training and Research Hospital, Istanbul, Turkey
2
Department of Pathology, University of Health Sciences, Sultan 2. Abdul Hamid Khan Educational and Research Hospital, Istanbul, Turkey
3
Department of Otolaryngology, University of Healt Sciences, Umraniye Training and Research Hospital, Istanbul, Turkey
Submission date: 2023-08-31
Final revision date: 2023-09-28
Acceptance date: 2023-10-04
Publication date: 2024-02-01
Corresponding author
Ilkay Tosun
Ilkay Tosun University of Health Sciences Umraniye Training and Research Hospital Istanbul, Turkey
Ilkay Tosun University of Health Sciences Umraniye Training and Research Hospital Istanbul, Turkey
Pol J Pathol 2023;74(4):282-285
KEYWORDS
TOPICS
ABSTRACT
Biphenotypic sinonasal sarcoma (BSNS), previously known as low-grade sinonasal sarcoma, is a rare tumour of the sinonasal tract, first described in 2012. It involves both myogenic and neural differentiation and is characterized by PAX3 rearrangement. MAML3 is the most frequent fusion partner of PAX3; however, its partner remains unidentified in a subset of cases. These tumours have significant local recurrence rates but lack metastatic potential. Here, we report a case of BSNS with PAX3/FOXO1 fusion and discuss its clinicopathological features and differential diagnosis.
REFERENCES (20)
1.
Lewis JT, Oliveira AM, Nascimento AG, et al. Low-grade sinonasal sarcoma with neural and myogenic features: a clinicopathologic analysis of 28 cases. Am J Surg Pathol 2012; 36: 517-525.
2.
Fritchie KJ, Jin L, Wang X, et al. Fusion gene profile of biphenotypic sinonasal sarcoma: an analysis of 44 cases. Histopathology 2016; 69: 930-936.
3.
Le Loarer F, Laffont S, Lesluyes T, et al. Clinicopathologic and molecular features of a series of 41 biphenotypic sinonasal sarcomas expanding their molecular spectrum. Am J Surg Pathol 2019; 43: 747-754.
4.
Rooper LM, Huang SC, Antonescu CR, et al. Biphenotypic sinonasal sarcoma: an expanded immunoprofile including consistent nuclear -catenin positivity and absence of SOX10 expression. Hum Pathol 2016; 55: 44-50.
5.
Jo VY, Mari¼o-Enriquez A, Fletcher CDM, et al. Expression of PAX3 distinguishes biphenotypic sinonasal sarcoma from histologic mimics. Am J Surg Pathol 2018; 42: 1275-1285.
6.
Sethi S, Cody B, Farhat NA, Pool MD, Katabi N. Biphenotypic sinonasal sarcoma: report of 3 cases with a review of literature. Hum Pathol (NY) 2021; 24: 200491.
7.
Wong WJ, Lauria A, Hornick JL, Xiao S, Fletcher JA, Marino- Enriquez A. Alternate PAX3-FOXO1 oncogenic fusion in biphenotypic sinonasal sarcoma. Genes Chromosomes Cancer 2016; 55: 25-29.
8.
El-Naggar AK, Chan JK, Grandis JR, Takata T, Sloot- weg PJ. WHO classification of head and neck tumors. Lyon IARC 2017, 40-41.
9.
Andreasen S, Bishop JA, Hellquist H, et al. Biphenotypic sinonasal sarcoma: demographics, clinicopathological characteristics, molecular features, and prognosis of a recently described entity. Virchows Arch 2018; 473: 615-626.
10.
Stelow EB, Bishop JA. Update from the 4th edition of the World Health Organization classification of head and neck tumours: tumors of the nasal cavity, paranasal sinuses and skull base. Head Neck Pathol 2017; 11: 3-15.
11.
Saito S, Ozawa H, Ikari Y, et al. Synovial sarcoma of the maxillary sinus: an extremely rare case with excellent response to chemotherapy. Onco Targets Ther 2018; 11: 483-488.
12.
Nonaka D, Chiriboga L, Rubin BP. Sox10: a Pan-Schwannian and melanocytic marker. Am J Surg Pathol 2008; 32: 1291-1298.
13.
Gross J, Fritchie K. Soft tissue special issue: biphenotypic sinonasal sarcoma: a review with emphasis on differential diagnosis. Head Neck Pathol 2020; 14: 32-42.
14.
Geramizadeh B, Marzban M, Churg A. Role of immunohistochemistry in the diagnosis of solitary fibrous tumor, a review. Iran J Pathol 2016; 11: 195-203.
15.
Agaram NP, LaQuaglia MP, Alaggio R, et al. MYOD1-mutant spindle cell and sclerosing rhabdomyosarcoma: an aggressive subtype irrespective of age. A reappraisal for molecular classification and risk stratification. Mod Pathol 2019; 32: 27-36.
16.
Wachtel M, Dettling M, Koscielniak E, et al. Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t (2;2) (q35; p23) translocation fusingPAX3 to NCOA1. Cancer Res 2004; 64: 5539-5545.
17.
Sumegi J, Streblow R, Frayer RW, et al. Recurrent t (2;2) and t (2;8) translocations in rhabdomyosarcoma without the canonical PAXFOXO1 fuse PAX3 to members of the nuclear receptor transcriptional coactivator family. Genes Chromosomes Cancer 2010; 49: 224-236.
18.
Wang X, Bledsoe KL, Graham RP, et al. Recurrent PAX3-MAML3 fusion in biphenotypic sinonasal sarcoma. Nat Genet 2014; 46: 666-668.
19.
Goldblum JR, Folpe AL, Weiss SW. Enzinger and weiss’s soft tissue tumors. 6th ed. Elsevier Saunders, Philadelphia 2014.
20.
Hung YP, Fletcher CDM, Hornick JL. Evaluation of pan-TRK immunohistochemistry in infantile fibrosarcoma, lipofbromatosis-like neural tumour and histological mimics. Histopathology 2018; 73: 634-644.
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
